Understanding Neuropsychiatric Fluctuations in Parkinson's Disease: From Mechanisms to Management
- 15 September 2026
- journal article
- Published by Wiley in Movement Disorders Clinical Practice
Abstract
Background: In patients with fluctuating Parkinson's disease (PD), treatment decisions predominantly focus on motor complications, whereas neuropsychiatric symptoms are often regarded as static. Neuropsychiatric fluctuations (NPF), however, are frequent, can rival or exceed motor symptoms in their impact on quality of life, and may predispose patients to persistent neuropsychiatric complications if left unrecognized. Objective: To propose a structured approach to the definition, mechanistic underpinnings, assessment, and management of NPF. Methods: Narrative review of clinical and mechanistic studies on NPF in patients with fluctuating PD, complemented by the authors’ clinical and research experience in the recognition and management of these phenomena. Findings were synthesized to provide a structured overview of their clinical characteristics, underlying mechanisms, assessment, and management, and to inform the proposed framework. Results: NPF are characterized by intradiurnal changes in mood, motivation, anxiety, and cognition that closely track the short‐term pharmacodynamics of dopaminergic therapy, reflecting transitions between relative dopaminergic deficiency during OFF periods and excessive dopaminergic stimulation during peak dose states. Converging clinical and mechanistic evidence supports dynamic fluctuations in dopaminergic tone within limbic and associative circuits as a key driver of NPF, whereas other neurotransmitter systems may also modulate their clinical expression. Recognition of NPF remains difficult because, unlike motor complications, they are less amenable to objective observation and quantification, patient self‐report is often limited by impaired insight, and commonly used PD rating scales fail to capture these phenomena. Consequently, effective management requires early identification and therapeutic strategies aimed at stabilizing dopaminergic tone within mesolimbic and mesocortical circuits. Timely detection and proactive treatment adjustments may help limit the progression and severity of neuropsychiatric complications over time. Conclusions: To move beyond a motor‐centric paradigm, the field requires consensus definitions, improved understanding of underlying mechanisms, validated assessment instruments, and clinical trials that prioritize NPF as primary outcomes.Keywords
This publication has 174 references indexed in Scilit:
- Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa TherapyJAMA Neurology, 2021
- Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson DiseaseJAMA Neurology, 2019
- Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson DiseaseJAMA Neurology, 2018
- Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson DiseaseJAMA Neurology, 2017
- Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional studyAnnals of Neurology, 2010
- Pathological gambling in Parkinson disease is reduced by amantadineAnnals of Neurology, 2010
- Impulse Control Disorders in Parkinson DiseaseArchives of Neurology, 2010
- Dopamine Agonist Withdrawal Syndrome in Parkinson DiseaseArchives of Neurology, 2010
- Compulsive drug use linked to sensitized ventral striatal dopamine transmissionAnnals of Neurology, 2006
- A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State EventsArchives of Neurology, 2001